Fair value · Atos SE (AEXAY) · updated 2026-09-04 · from 20-F FY2025
Everything below is unaffected: the filed statements, the filing they came from, and AEXAY’s growth history are all as reported.
20-F FY2025 · fiscal year ended 2025-12-31 · filed 2025-12-31
Trailing-twelve-month EPS also uses the quarterly 6-Ks through Q2 FY2026 (filed 2026-06-30).
Open the 20-F list on sec.govAt least two methods need a usable value to draw a range with these inputs.
No preset range for this company yet.
The two ranges are identical because every input sits on a preset.
We don’t tell you what AEXAY is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has AEXAY’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
Financials are filed in EUR; our prices are in USD, so these methods need a conversion we do not yet publish.
Preset inputs — revenue-driven DCF from the latest filing
Implied by today’s price
Financials are filed in EUR; our prices are in USD, so these methods need a conversion we do not yet publish.
Not solvable from the price — Financials are filed in EUR; our prices are in USD, so these methods need a conversion we do not yet publish. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what AEXAY has actually filed, and the AI chat will reason it through with you.
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
How long stage-1 growth lasts.
Slower growth after stage 1, before the terminal phase.
Growth forever after the two stages. Above ~3% is rarely justified.
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
| Year | Stage | FCF | Present value |
|---|---|---|---|
| 1 | Stage 1 | $-91M | $-76M |
| 2 | Stage 1 | $-96M | $-67M |
| 3 | Stage 1 | $-101M | $-59M |
| 4 | Stage 1 | $-106M | $-51M |
| 5 | Stage 1 | $-111M | $-45M |
| 6 | Stage 2 | $-114M | $-38M |
| 7 | Stage 2 | $-117M | $-33M |
| 8 | Stage 2 | $-120M | $-28M |
| 9 | Stage 2 | $-123M | $-24M |
| 10 | Stage 2 | $-126M | $-21M |
Inputs from the filing
Financials are filed in EUR; our prices are in USD, so these methods need a conversion we do not yet publish.
20-F FY2025 · period ended 2025-12-31 · filed 2025-12-31 · sec.gov
Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for AEXAY